OptumRx generic pipeline forecast
|
|
|
- Berniece Jacobs
- 5 years ago
- Views:
Transcription
1 OptumRx generic pipeline forecast 2017 Daytrana methylphenidate Noven Therapeutics Transdermal patch All Epiduo adapalene/benzoyl peroxide Endo Gel All Norvir ritonavir AbbVie Capsule; tablet All Proventil HFA albuterol sulfate Merck Inhalation All Travatan Z travoprost Alcon/Novartis Ophthalmic All Zavesca miglustat Actelion Capsule All Sprix ketorolac Egalet Intranasal All Safyral drospirenone/ethinyl estradiol/levomefolate Axiron testosterone Lilly Bayer Tablet All H Transdermal solution All H Relpax eletriptan Pfizer Tablet All H Tracleer bosentan Actelion Tablet All H Syprine trientine Valeant Capsule All Q Betimol timolol Oak/Akorn Ophthalmic All Mid-2017 Strattera atomoxetine Eli Lilly Capsule All Gabitril tiagabine Cephalon/Teva Tablet 12 mg, 16 mg Copaxone glatiramer Teva Neuroscience Subcutaneous 40 mg/ml H Aloxi palonosetron Helsinn/Eisai Intravenous All Q Butrans buprenorphine Purdue Transdermal patch All Q Vigamox moxifloxacin Alcon/Novartis Ophthalmic All Asmanex HFA mometasone furoate Merck Inhalation All Angeliq drospirenone/estradiol Bayer Tablet All Cancidas caspofungin Merck Injection All Effient prasugrel Eli Lilly Tablet All Lemtrada alemtuzumab Sanofi Intravenous All Byetta exenatide AstraZeneca Subcutaneous All optum.com/optumrx 1
2 Fentora fentanyl Teva Tablet, buccal All Uceris Foam budesonide Valeant Rectal foam All Adcirca tadalafil Eli Lilly/United Therapeutics Tablet All Invanz ertapenem Merck Intravenous All Menostar estradiol Bayer Transdermal patch All Ganirelix ganirelix acetate Organon/Merck Injection All Kaletra lopinavir/ritonavir AbbVie Tablet All Reyataz atazanavir Bristol-Myers Squibb Capsule All Sustiva efavirenz Bristol-Myers Squibb Tablet 600 mg Viagra sildenafil Pfizer Tablet All Viread tenofovir disoproxil fumarate Gilead Tablet 300 mg s Advair Diskus fluticasone/salmeterol xinafoate GlaxoSmithKline Inhalation All 2018 Minivelle estradiol Noven Transdermal patch All 2018 Proair HFA albuterol sulfate Teva Inhalation All 2018 Samsca tolvaptan Otsuka Tablet All 2018 Trisenox arsenic trioxide Cephalon/Teva Intravenous All 2018 Zytiga abiraterone Janssen Tablet All 2018 Humira adalimumab AbbVie Subcutaneous All Clolar clofarabine Genzyme/Sanofi Intravenous All H Suprenza phentermine Citius/Akrimax Tablet, orally disintegrating All H Lexiva fosamprenavir ViiV Healthcare Tablet; suspension All Q Zortress everolimus Novartis Tablet All Q Avastin bevacizumab Genentech Injection All Q Epogen epoetin alfa Amgen Subcutaneous; intravenous All Q Herceptin trastuzumab Genentech/Roche Intravenous All Q Neulasta pegfilgrastim Amgen Subcutaneous All Q Procrit epoetin alfa Janssen Subcutaneous; intravenous All Q Androgel testosterone AbbVie Gel 1.62% Forfivo XL bupropion IntelGenX/Edgemont All optum.com/optumrx 2
3 Istodax romidepsin Celgene Intravenous All Makena hydroxyprogesterone caproate Lumara Health/Amag Pharmaceuticals Intramuscular All Treximet naproxen/sumatriptan succinate Pernix Tablet All Nuvaring etonogestrel/ethinyl estradiol Merck Vaginal ring All Cialis tadalafil Eli Lilly Tablet All Invega Trinza paliperidone palmitate Janssen Intramuscular, extended-release All Abstral fentanyl citrate Sentynl Tablet, sublingual All Emsam selegiline Somerset/Mylan Transdermal patch All Remodulin treprostinil United Therapeutics Injection All Levitra vardenafil Merck/Bayer Tablet All Q Letairis ambrisentan Gilead Sciences Tablet All Q Acanya clindamycin/benzoyl peroxide Valeant Gel All Ampyra dalfampridine Acorda All Xenical orlistat Roche Capsule All Moviprep PEG-3350/sodium sulfate/sodium chloride/potassium chloride/sodium ascorbate/ascorbic acid Salix/Valeant Oral solution All Sensipar cinacalcet Amgen Tablet All Tolak fluorouracil Hill Dermaceuticals Cream All Pylera Bismuth subcitrate potassium/metronidaz ole/tetracycline Allergan/Aptalis Capsule All Q Rapaflo silodosin Allergan Capsule All Q Enbrel etanercept Amgen Subcutaneous All Q Finacea azelaic acid Bayer Gel All Pulmicort Flexhaler budesonide AstraZeneca Inhalation All Astagraf XL tacrolimus Astellas Basaglar insulin glargine recombinant Eli Lilly/Boehringer Ingelheim Capsule, extendedrelease All Subcutaneous All Canasa mesalamine Forest/Allergan Rectal suppository All Elidel pimecrolimus Valeant Cream All Xolair omalizumab Roche/Genentech Intravenous All optum.com/optumrx 3
4 2019 s Cuvposa Merz glycopyrrolate Oral solution All 2019 Rozerem Takeda ramelteon Tablet All 2019 Tarceva OSI Pharma/Genentech/ Pfizer erlotinib Tablet All 2019 Omnaris Sunovion/Takeda ciclesonide Intranasal All H Bepreve Bausch & Lomb/Valeant bepotastine Ophthalmic All Latuda Sunovion lurasidone Tablet All Tekturna Novartis aliskiren Tablet All Tekturna HCT Novartis Aliskiren/ hydrochlorothiazide Tablet All Zyclara Medicis imiquimod Cream All Advate Baxalta antihemophilic factor (recombinant), plasma/albumin-free method Intravenous All Gilenya Novartis fingolimod Capsule All Korlym Corcept mifepristone Tablet All Ranexa Gilead ranolazine All Azasite Akorn azithromycin Ophthalmic All Emend Merck fosaprepitant dimeglumine Intravenous All Faslodex AstraZeneca fulvestrant Intramuscular All Actemra Roche/Chugai tocilizumab Benefix Pfizer coagulation factor IX (recombinant) Intravenous; subcutaneous All Intravenous All Cetrotide EMD Serono cetrorelix Subcutaneous All Exjade Novartis deferasirox Tablet All Flector Pfizer diclofenac epolamine Transdermal patch All Vesicare Astellas solifenacin Tablet All Epaned Kit Silvergate enalapril Oral solution All Dyloject Hospira/Pfizer/Javelin diclofenac Intravenous All Levemir Novo Nordisk insulin detemir recombinant Subcutaneous All Lyrica Pfizer pregabalin Capsule; solution All Rescriptor ViiV Healthcare delavirdine Tablet All = may launch during the stated date or later optum.com/optumrx 4
5 optum.com/optumrx The information contained herein is compiled from various sources and is provided for informational purposes only. Due to factors beyond the control of OptumRx, information related to prospective drug launches is subject to change without notice. This information should not be solely relied upon for formulary decision-making purposes. OptumRx specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum company a leading provider of integrated health services. Learn more at optum.com. All Optum trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners. This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx. RxOutlook is published by the OptumRx Clinical Services Department Optum, Inc. All rights reserved. ORX6204B_ optum.com/optumrx 5
OptumRx generic pipeline forecast
OptumRx generic pipeline forecast 2017 DAYTRANA Noven Therapeutics methylphenidate Transdermal patch All 2017 NORVIR AbbVie ritonavir Capsule; tablet All 2017 PROVENTIL HFA Merck albuterol sulfate Inhalation
OptumRx generic pipeline forecast
OptumRx generic pipeline forecast 2018 DAYTRANA methylphenidate Noven Therapeutics Transdermal patch All 2018 NORVIR ritonavir AbbVie Capsule; tablet All 2018 PROVENTIL HFA albuterol sulfate Merck Inhalation
ESTIMATED LAUNCH DATE* Sensipar cinacalcet Amgen Mar 2018 Endocrine Disorders High. Altoprev lovastatin ER Andrx Mar 2018 High Blood Cholesterol Low
Topicort 0.25% Topical Spray desoximetasone topical spray Taro Mar 2018 Skin Sensipar cinacalcet Amgen Mar 2018 Endocrine Disorders High Altoprev lovastatin ER Andrx Mar 2018 High Blood Cholesterol Ketek
2014 DTC National Advertising Awards Finalists
2014 DTC National Advertising Awards Finalists All Gold, Silver, and Bronze winners will be announced at the DTC National Advertising Awards Dinner on April 23. Each therapeutic category winner from Television,
Blue Cross and Blue Shield of Minnesota GenRx Formulary Updates
Blue Cross and Blue Shield of Minnesota GenRx Formulary Updates July 2018 TRADE NAME (generic name) or generic name ADVAIR DISKUS (fluticasone-salmeterol aer powder ba 100-50 mcg/dose) Brand Addition ADVAIR
ANTIDEPRESSANTS. Details. Step Therapy 2017 Last Updated: 5/23/2017
ANTIDEPRESSANTS EMSAM PATCH 24 HOUR 12 MG/24HR TRANSDERMAL EMSAM PATCH 24 HOUR 6 MG/24HR TRANSDERMAL EMSAM PATCH 24 HOUR 9 MG/24HR TRANSDERMAL FETZIMA CAPSULE EXTENDED RELEASE 24 HOUR 120 MG FETZIMA CAPSULE
ANTIDEPRESSANTS. Details. Step Therapy 2018 Last Updated: 8/21/2018
ANTIDEPRESSANTS EMSAM PATCH 24 HOUR 12 MG/24HR TRANSDERMAL EMSAM PATCH 24 HOUR 6 MG/24HR TRANSDERMAL EMSAM PATCH 24 HOUR 9 MG/24HR TRANSDERMAL FETZIMA CAPSULE EXTENDED RELEASE 24 HOUR 120 MG ORAL FETZIMA
Notice of Mid-Year Changes to 2019 Paramount Enhanced Formulary
Notice of Mid-Year s to 2019 Paramount Enhanced Formulary Paramount Elite (HMO) may immediately remove a brand name drug on our List if we are replacing it with a new generic drug that will appear on the
Memorial Hermann Advantage HMO February 2019 Formulary Addendum
Memorial Hermann Advantage HMO February 2019 Formulary Addendum Changes may have occurred since the printing of your current Memorial Hermann Advantage HMO Formulary. Medications that may have been added
Medication and Dose 10/04/ /05/2016 Total % Change Since 10/2012 ABILIFY 10 MG TABLET $18.76 $ %
Table Comparing NADAC prices for select brand name prescription medications on October 4, 2012 and October 5, 2016 to show how much prices have gone up for these medications. These medications increased
3 Tier Formulary Additions
3 Tier Formulary Additions Drug Name Tier Category Management ACCU-CHECK GUIDE ME GLUCOSE METER 3 Diabetic Supplies Step Therapy applies pyridostigmine bromide 60mg/5ml syrup 1 Antimyasthenic Agents New
Granite Alliance Insurance Company (PDP) 2018 Step Therapy Criteria Last Updated: 10/23/18
Granite Alliance Insurance Company (PDP) 2018 Step Therapy Criteria Last Updated: 10/23/18 Granite Alliance requires step therapy for certain drugs. This means prior to receiving a drug with a step therapy
2019 Drug List Negative Changes
2019 Drug List Negative Changes Updated 03/26/2019 If you are taking a drug that is removed from the formulary (also known as the Drug List), we will tell you. We will also tell you if we add any restrictions
FORMULARY UPDATES TO DENVER HEALTH MEDICAID CHOICE (DHMC) AND CHILD HEALTH PLAN PLUS (CHP+) PLANS
FORMULARY UPDATES TO DENVER HEALTH MEDICAID CHOICE (DHMC) AND CHILD HEALTH PLAN PLUS (CHP+) PLANS DHMC/CHP+ may add or remove drugs from the formulary or make changes to restrictions on formulary drugs
CONTACT POLPHARMA GROUP POLPHARMA B2B
DOSSIER FDFLIST Product name Pharmaceutical form Strength Reference Therapeutic class ALIMENTARY TRACT & METABOLISM 1. Esomeprazole sodium or injection 40 mg Nexium / AstraZeneca Antiulcerant 2. Omeprazole
Health Partners Medicare Prime 2019 Formulary Changes
Health Partners Medicare Prime 2019 Formulary Changes Changes occur, for example, because new drugs come on the market, a drug is moved to a different cost-sharing level (tier), or a generic version becomes
Superior Select Health Plans: Tribute-1 Tier May 2018 Formulary Addendum
Superior Select Health Plans: Tribute-1 Tier May 2018 Formulary Addendum Below is a list formulary changes for the benefit year 2018. This is not a complete list of drugs covered by the Part D plan. The
FORMULARY UPDATES TO DENVER HEALTH MEDICAID CHOICE (DHMC) AND CHILD HEALTH PLAN PLUS (CHP+) PLANS
FORMULARY UPDATES TO DENVER HEALTH MEDICAID CHOICE (DHMC) AND CHILD HEALTH PLAN PLUS (CHP+) PLANS DHMC/CHP+ may add or remove drugs from the formulary or make changes to restrictions on formulary drugs
NEW PATENTED MEDICINES REPORTED TO PMPRB 2011 (UPDATE AS OF NOVEMBER 30, HIGHLIGHTED)
HUMAN DRUGS NEW PATENTED MEDICINES REPORTED TO PMPRB 2011 COMPANY BRAND NAME CHEMICAL NAME DIN THERAPEUTIC USE DATE OF FIRST SALE Abbott Laboratories Limited Norvir 100 mg/tablet ritonavir 02357593 HIV
US pharmaceutical market: trends, issues, forecast. Doug Long Vice President Industry Relations IMS Health
US pharmaceutical market: trends, issues, forecast Doug Long Vice President Industry Relations IMS Health 2006 Strategic management review The World Pharmaceutical Market All reproduction rights, quotations,
Step Therapy Medications
Step Therapy Medications Step Therapy (ST PA ) is an automated form of prior authorization. It encourages the use of therapies that should be tried first, before other treatments are covered, based on
2019 Drug List Negative Changes
2019 Drug List Negative Changes Updated 03/26/2019 If you are taking a drug that is removed from the formulary (also known as the Drug List), we will tell you. We will also tell you if we add any restrictions
MEDICAID QUANTITY LIMIT DRUG LIST
MEDICAID QUANTITY LIMIT DRUG LIST PH51-R-02162018 Brand Name Generic Name Dosage Form Tier Quantity Limit Details Cambia Diclofenac Potassium PACK Tier 2 QL: 9 per 30 days Fentanyl (12 Mcg/Hr, 25 Mcg/
TECHNICAL APPENDIX: A PERSPECTIVE ON PRESCRIPTION DRUG COPAYMENT COUPONS
TECHNICAL APPENDIX: A PERSPECTIVE ON PRESCRIPTION DRUG COPAYMENT COUPONS METHODS FOR DETERMINING COPAY COUPON STATUS The copay coupon information comes from www.internetdrugcoupons.com (IDC). These data
Select Inhaled Respiratory Agents
Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided
Step Therapy Approval Criteria
Effective Date: 01/01/2019 This document contains for the following medications: 1. Colcrys (colchicine) 2. Dovonex (calcipotriene) 3. Enbrel (etanercept) 4. Humira (adalimumab) 5. Imitrex Injection vial
Aetna Better Health of Illinois Medicaid Formulary Updates
October 2017 o DOXYLAMINE SUCCINATE 25mg-QL o DULOXETINE CAP 40MG DR-QL o GUANFACIN ER TABS (all strengths)-ql o TOBRAMYCIN NEBU SOLUTION- PA August 2017 Aetna Better Health of Illinois Medicaid 2017 Formulary
JANUVIA 50 MG TABLET BYDUREON 2 MG/0.65 ML JARDIANCE 10 MG TABLET SUBCUTANEOUS PEN INJECTOR JARDIANCE 25 MG TABLET BYDUREON BCISE 2 MG/0.
ANTI DIABETICS BYDUREON 2 MG SUBCUTANEOUS JANUVIA 25 MG TABLET EXTENDED RELEASE SUSPENSION JANUVIA 50 MG TABLET BYDUREON 2 MG/0.65 ML JARDIANCE 10 MG TABLET SUBCUTANEOUS PEN INJECTOR JARDIANCE 25 MG TABLET
Inhaled bronchodilators relax constricted airways and treat the noisy part of asthma: coughing, wheezing, choking and shortness of breath.
Inhaled bronchodilators relax constricted airways and treat the noisy part of asthma: coughing, wheezing, choking and shortness of breath. AccuNeb inhalation 0.021% solution: 0.63mg/3mL 3-4 times solution
Michigan Department of Community Health Quantity Limitations
Abstral (fentanyl) sl tab all strength Acetaminophen Actonel Actonel 35mg Adderall XR 5mg, 10mg, 15mg 240 per 34 days 3 gm/day 2 every 28 days 4 every 28 days Advair Diskus. No more than 180 every 30 days
2018 CareOregon Advantage Part D Formulary Changes
2018 CareOregon Advantage Part D Formulary Changes Abbreviations: AGE = Age Restriction; PA = Prior Authorization Required; QL = Quantity Limit; ST = Step Therapy Required; LD = Limited Distribution; BvD
PULMONARY ARTERIAL HYPERTENSION AGENTS
Approvable Criteria: PULMONARY ARTERIAL HYPERTENSION AGENTS Brand Name Generic Name Length of Authorization Adcirca tadalafil Calendar Year Adempas riociguat Calendar Year Flolan epoprostenol sodium Calendar
List of Designated High-Cost Drugs
List of Designated High-Cost Drugs UPDATED APRIL 25, 2018 For details on the High-Cost Drug policy, see Section 5.8 of the PharmaCare Policy Manual. Recent updates appear in red. Deletions are listed at
TRICARE Uniform Formulary. Pre-Authorization Requirements
TRICARE Uniform Formulary Pre-Authorization Requirements The Department of Defense (DoD) requires pre-authorization on select medications. These medications are on the DoD s pre-authorization list because
Recommended comparator products: Medicines for HIV/AIDS and related diseases
Recommended comparator products: Medicines for HIV/AIDS and related diseases Comparator products should be purchased from a well regulated market with stringent regulatory authority 1. Invited medicinal
Pharmacy and Therapeutics (P&T) Committee Provider Update
Pharmacy and Therapeutics (P&T) Committee Provider Update THIRD QUARTER 2017 Presbyterian Health Plan, Inc. Presbyterian Insurance Company, Inc. P&T Committee Decisions Effective August 15, 2017 Dear Healthcare
2018 OPEN FORMULARY Updates
January, 2018 01/01/2018 OPDIVO nivolumab 01/01/2018 KEVZARA sarilumab 01/01/2018 KEVZARA sarilumab 01/01/2018 AIMOVIG AUTOINJECTOR,AIMOVIG AUTOINJECTOR (2 PACK) erenumab-aooe 01/02/2018 glucose in water
Pain Oral-Intranasal Fentanyl (Abstral, Actiq, Fentora, Lazanda, Onsolis, Subsys)
Pennsylvania Employees Benefit Trust Fund (PEBTF) and n- Medicare Eligible Retired Employees Health Program (REHP), Step Therapy and Quantity Limit List Your doctor needs to get prior authorization for
PRESCRIPTION DRUG PROGRAM FORMULARY UPDATES
PRESCRIPTION DRUG PROGRAM FORMULARY UPDATES Generic Additions These generic drugs recently became available in the marketplace. When these generic drugs became available, we began covering them at the
Step Therapy Criteria
ADCIRCA ADCIRCA Coverage will be provided if the member has filled a prescription for sildenafil (at least a 30 day supply within the past 365 ) ELIDEL 76-F ELIDEL Coverage will be provided if the member
How Safe and Innovative Are First-in-Class Drugs Approved by Health Canada: A Cohort Study
RESEARCH PAPER How Safe and Are First-in-Class Drugs Approved by Health Canada: A Cohort Study L innocuité et l aspect innovant des nouvelles classes de médicaments approuvés par Santé Canada : une étude
ABILIFY INJ. Products Affected Step 2: ABILIFY MAINTENA PREFILLED SYRINGE 300 MG INTRAMUSCULAR ABILIFY MAINTENA PREFILLED SYRINGE 400 MG INTRAMUSCULAR
ABILIFY INJ ABILIFY MAINTENA PREFILLED SYRINGE 300 MG ABILIFY MAINTENA PREFILLED SYRINGE 400 MG ABILIFY MAINTENA SUSPENSION RECONSTITUTED ER 300 MG Claim will pay automatically for ABILIFY MAINTENA if
TABLE OF CONTENTS 1 Table of Contents 2 Introduction 3 Key Marketed Products
TABLE OF CONTENTS 1 Table of Contents 1.1 List of Tables 1.2 List of Figures 2 Introduction 2.1 Epidemiology 2.2 Symptoms 2.3 Etiology 2.4 Pathophysiology 2.5 Co-morbidities and Complications 2.6 Classification
UPMC for You Pharmacy and Therapeutics Committee Meeting July 27, 2010 meeting
1. Call to order: The meeting was called to order at 7:10 a.m. UPMC for You Pharmacy and Therapeutics Committee Meeting July 27, 2010 meeting 2. Review of the minutes: The minutes of the April 6, 2010
Mercy Care Plan. Acyclovir Ointment. Products Affected. acyclovir ointment 5 % external Details. Criteria. Requires use of oral Acyclovir
Acyclovir Ointment Mercy Care Plan acyclovir ointment 5 % external Requires use of oral Acyclovir 1 Adcirca ADCIRCA TABLET 20 MG ORAL Requires use of Sildenafil 2 Albenza ALBENZA TABLET 200 MG ORAL Requires
University System of Georgia Prior Authorization, Step Therapy and Quantity Limit List (Updated 1/1/2016)
University System of Georgia, Step Therapy and Quantity Limit List (Updated 1/1/2016) (PA) Your doctor will need to obtain a prior authorization for the drugs listed below, before your prescription drug
THE CORPORATE REPUTATION OF PHARMA 2015 THE PERSPECTIVE OF 139 PATIENT GROUPS with an interest in DIABETES
THE CORPORATE REPUTATION OF PHARMA 2015 THE PERSPECTIVE OF 139 PATIENT GROUPS with an interest in DIABETES PUBLISHED AUGUST 2016 There is growing distrust of pharma in light of several recent and dramatic
Medicare Part D 2017 Formulary Changes Service To Senior
Medicare Part D 2017 Formulary Changes Service To Senior Inter Valley Health Plan may add or remove drugs from our formulary during the year. If we remove a drug from our formulary, add prior authorization,
DOSSIER LIST. tlo_seledyn.pdf :38:01 CMY K CM MY CY
tlo_seledyn.pdf 1 22.08.2017 14:38:01 C M Y CM MY CY CMY K DOSSIER LIST AVAILABLE DOSSIERS THERAPEUTIC CLASS / MAIN INDICATION LACTOSE FREE ZONE IV CPP FEASIBILITY ALIMENTARY TRACT & METABOLISM 1. Esomeprazole
Quarterly pharmacy formulary change notice
Quarterly pharmacy formulary change notice The formulary changes listed in the table below were reviewed and approved at our second quarter 2018 Pharmacy and Therapeutics Committee meeting. Effective October
Health Partners Medicare Special 2018 Formulary Changes
Health Partners Medicare Special 2018 Changes Changes occur, for example, because new drugs come on the market, a drug is moved to a different cost-sharing level (tier), or a generic version becomes available.
ANTICONVULSANTS. Details. Step Therapy Criteria Date Effective: April 1, 2019
Step Therapy Date Effective: April 1, 2019 ANTICONVULSANTS APTIOM TABLET 200 MG ORAL APTIOM TABLET 400 MG ORAL APTIOM TABLET 600 MG ORAL APTIOM TABLET 800 MG ORAL BANZEL SUSPENSION 40 MG/ML ORAL BANZEL
Health Net Health Plan of Oregon, Inc. Oregon Drugs with a quantity limit Effective January 1, 2015 (Published December 15, 2014)
Health Net Health Plan of Oregon, Inc. Oregon Drugs with a quantity limit Effective January 1, 2015 (Published December 15, 2014) Abstral SL Actonel 35mg Limited to 4 s per month. Actonel 5,30mg adapalene
PRESCRIPTION DRUGS REQUIRING PRIOR AUTHORIZATION
Abstral fentanyl citrate oral tablet Controlled Dangerous substance Actemra tocilizumab Monoclonal antibody Acthar corticotropin Hormone Actimmune interferon gamma 1b Interferon Actiq fentanyl citrate
Quarterly pharmacy formulary change notice
Quarterly pharmacy formulary change notice Summary of change: The Pharmacy and Therapeutics Committee (P&T) reviewed and approved the formulary changes listed in the table below on March 29, 2016. What
APREPITANT ARMODAFINIL BELSOMRA BUPAP BUPRENORPHINE HCL BUTALBITAL-ACETAMINOPHEN BUTALBITAL-APAP-CAFF-COD BUTALBITAL-APAP-CAFFEINE
APREPITANT Aprepitant Oral Capsule 125, 40, 80 Aprepitant Oral Capsule 80 & 125 Quantity Limit: 8 EA Per 30 Days Quantity Limit: 12 EA Per 30 Days ARMODAFINIL Armodafinil Oral Tablet 150, 200, 250, 50
2016 PRESCRIPTION DRUG LIST UPDATES
2016 PRESCRIPTION DRUG LIST UPDATES Evergreen Health 1 st Quarter Below are key updates to the four-tier EHB Prescription Formulary, effective January 1, 2016. Please consult the full formulary for more
MDwise Self-Administered Codes for Medical
The following codes are associated with medications that can be self-administered by the patient or a caregiver. As a result, MDwise will transfer coverage of these self-administered medications exclusively
5-ASA. Products Affected Dipentum 250 mg capsule. Details. Lialda 1.2 gram tablet,delayed release
5-ASA Dipentum 250 mg capsule Lialda 1.2 gram tablet,delayed release You are required to have previous therapy with balsalazide, Delzicol, Apriso, or Asacol HD before we will cover Lialda or Dipentum.
Quarterly pharmacy formulary change notice
Provider Bulletin October 2018 Quarterly pharmacy formulary change notice The formulary changes listed in the table below apply to all Anthem HealthKeepers Plus patients. The changes listed in the table
Quantity Limits 2016 Paramount Medicare Formulary Formulary ID: Version 26 Updated: 11/1/2016
Quantity Limits 2016 Paramount Medicare Formulary Formulary ID: 16162 Version 26 Updated: 11/1/2016 ANALGESICS acetaminophen w/ codeine (300-15 mg, 300-30 mg, 300-60 mg) acetaminophen w/ codeine soln 120-12
STEP THERAPY ALGORITHMS PUP Select Formulary
The Step Therapy drug will be dispensed if the drug has been dispensed within 120 days of current fill or if alternative (Step 1) drugs have been used first. If the member s prescription claim fails the
Oregon Health Plan prescription benefit updates
Oregon Health Plan prescription benefit updates EOCCO s prescription program is a pharmacy benefit that offers members a choice of safe and effective medication treatments. The program also helps you save
September 2018 Pharmacy & Therapeutics Committee Decisions
UCare s Pharmacy and Therapeutics Committee (P&T) is a group of physicians and pharmacists that meet throughout the year to make changes to UCare (approved drug list). These changes are reviewed based
J Jubilant Pharma Group, catering to Dosage
DOSAGE FORMULATIONS Jubilant Generics, is one of the business arms of J Jubilant Pharma Group, catering to Dosage Formulations (DF) & Active Pharmaceutical Ingredients (API) business segment across developed
Oncology Pipeline Analytics
Oncology Pipeline Analytics Trials, Drug Classes, Indications, Correlations and Strategies Report Brochure O n c o l o g y P i p e l i n e A n a l y t i c s Greystone Research Associates is pleased to
2016 Drug Blockbusters and Patent Expiration Review
February 23, 2016 2016 Drug Blockbusters and Patent Expiration Review Nicolle Rychlick, PharmD Director, Clinical Integration and Implementation 1 Disclosure Nicolle Rychlick, Pharm.D., has nothing to
2018 Formulary Notice of Change Prescription Drug Plans
2018 Formulary Notice of Change Prescription Drug Plans WellCare Prescription Insurance, Inc. Plans in all states: WellCare Classic (PDP) WellCare may add or remove drugs from our formulary during the
Michigan Department of Health & Human Services Quantity Limitations
Abstral (fentanyl) sl tab all strength Acetaminophen Actonel Actonel 35mg Adderall XR 5mg, 10mg, 15mg Advair Diskus Advair HFA Aero Chambers and Spacers Aerobid Aerobid M Albuterol HFA 90mcg Akynzeo Aldara
INSIGHT on the Issues
INSIGHT on the Issues AARP Public Policy Institute Rx Watchdog Report: Drug Prices Continue to Climb Despite Lack of Growth in General Inflation Rate AARP s Public Policy Institute finds that average manufacturer
2014 Quantity Limits (QL) Criteria
2014 Quantity Limits (QL) Criteria Certain drugs covered through your EmblemHealth Medicare HMO/PPO Medicare Plan are covered for only a limited quantity. We do this to ensure compliance with the US Food
AVAILABLE DOSSIERS. Product name Pharmaceutical form Strength Reference Therapeutic class
DOSSIER LIST AVAILABLE DOSSIERS Product name Pharmaceutical form Strength Reference Therapeutic class ALIMENTARY TRACT & METABOLISM Esomeprazole sodium Omeprazole sodium injection / 40 mg Nexium / AstraZeneca
Emblem Medicaid 3Q18 Formulary Updates
ALKERAN 2 MG TABLET Removed from Formulary 7/9/2018 AMITIZA 24 MCG CAPSULES Removed from Formulary 7/9/2018 AMITIZA 8 MCG CAPSULE Removed from Formulary 7/9/2018 avo cream topical emulsion Removed from
Formulary Changes. One mission: you TABLE A. FORMULARY CHANGES 7/1/2018: Commercial 3-Tier Formulary. Commercial 4-Tier Formulary
One mission: you Changes July 1, 2018 Blue Cross of Idaho reviews its formularies (covered drug lists) periodically to allow members access to new drugs and to provide safe, cost effective options for
2014 Preferred Drug List An evidence-based pharmacy program that works for you
2014 Preferred Drug List An evidence-based pharmacy program that works for you What is the Moda Health Preferred Drug Program? The Moda Health Preferred Drug Program is a pharmacy program that is designed
Quarterly pharmacy formulary change notice
MEDICAID PROVIDER BULLETIN October 2018 The formulary changes listed in the table below were reviewed and approved at the second-quarter 2018 Pharmacy and Therapeutics Committee meeting. Effective October
ARISTADA. Products Affected Step 2: ARISTADA PREFILLED SYRINGE 1064 MG/3.9ML INTRAMUSCULAR ARISTADA PREFILLED SYRINGE 441 MG/1.
ARISTADA ARISTADA PREFILLED SYRINGE 1064 MG/3.9ML INTRAMUSCULAR ARISTADA PREFILLED SYRINGE 441 MG/1.6ML INTRAMUSCULAR ARISTADA PREFILLED SYRINGE 662 MG/2.4ML INTRAMUSCULAR ARISTADA PREFILLED SYRINGE 882
First to Market or 505 (b)2 CMC Considerations IPAC-RS/UF Orlando Inhalation Conference Orlando, Florida
First to Market or 505 (b)2 CMC Considerations IPAC-RS/UF Orlando Inhalation Conference Orlando, Florida Prasad Peri, Ph.D., Branch Chief, ONDQA, FDA March 19, 2014 1 Topics for discussion Introduction
Quarterly pharmacy formulary change notice
Provider Bulletin June 24, 2016 Summary of change The Pharmacy and Therapeutics Committee reviewed and approved the formulary changes listed in the table below on March 29, 2016. What this means to you
Recommended Comparator Products: Medicines for HIV/AIDS and Related Diseases
Medicines for HIV/AIDS and Related Diseases Comparator products should be purchased from a well-regulated market with a stringent regulatory authority. 1 Invited medicinal products Abacavir, 60 mg, 300
2016 Drug Trend Report COMMERCIAL
2016 Drug Trend Report COMMERCIAL THERAPY CLASS REVIEW MARKET FACTORS METHODOLOGY Table of contents Introduction 3 Therapy class review 6 Bending the curve on drug spending in 2016 7 Top 15 therapy classes
Changes to the 2018 BlueCross Secure SM (HMO) & BlueCross Total SM (PPO) Formularies
Changes to the 2018 BlueCross Secure SM (HMO) & BlueCross Total SM (PPO) Formularies BlueCross BlueShield of South Carolina may add or remove drugs from the formulary during the year. If we remove drugs
STEP THERAPY CRITERIA
STEP THERAPY This is a complete list of drugs that have written coverage determination policies. Drugs on this list do not indicate that this particular drug will be covered under your medical or prescription
June 2018 Pharmacy & Therapeutics Committee Decisions
UCare s Pharmacy and Therapeutics Committee (P&T) is a group of physicians and pharmacists that meet throughout the year to make changes to the UCare formulary (approved drug list). These changes are reviewed
Prescription benefit updates Individual/small group
Prescription benefit updates Individual/small group Moda Health s prescription program is a pharmacy benefit that offers members a choice of safe and effective medication treatments. The program also helps
Your prescription benefit updates Formulary Updates - Effective January 1, 2019
Your prescription benefit updates Formulary Updates - Effective January 1, 2019 Medications are grouped by the conditions they treat. Each medication is placed in a tier that shows the amount you will
Pharmacy Updates Summary
All of the following changes were reviewed and approved by the SFHP Pharmacy & Therapeutics (P&T) Committee on 04/15/2015 Effective date: 05/15/2015 Therapeutic Classes reviewed: Testosterone replacement
PBS Growth. The changing composition of the PBS. PBS Top 10 drugs in transition. Shifting sands for industry as generic volume soars
PBS Growth The changing composition of the PBS PBS Top 10 drugs in transition Shifting sands for industry as generic volume soars The under co-payment market PBS Update 2014-15 Growth in PBS spending was
Step Therapy Criteria 2019
Step Therapy 2019 For information on obtaining an updated coverage determination or an exception to a coverage determination please call Freedom Health Member Services at 1-800-401-2740 or, for TTY/TDD
2018 Formulary Update
MEDICARE ADVANTAGE BlueShield of Northeastern New York 2018 Formulary Update BlueShield of Northeastern New York has updated its formulary (drug list) since its original publication in January 2018. This
Mercy Care ALBENDAZOLE. Products Affected. ALBENZA TABLET 200 MG ORAL Details. Criteria. Refer to PA Guideline for approval criteria
ALBENDAZOLE Mercy Care ALBENZA TABLET 200 MG ORAL Refer to PA Guideline for approval criteria 1 BRIMONIDINE-TIMOLOL COMBIGAN SOLUTION 0.2-0.5 % OPHTHALMIC Requires use of separate ingredients for at least
2017 Formulary Changes Year to Date
2017 Formulary Changes Year to Date Health Choice Arizona may add or remove drugs from our formulary during the year. If we remove drugs from our formulary, add prior authorization, quantity limits and/or
Drug Pipeline Monthly Update
Drug Pipeline Monthly Update Critical updates in an ever changing environment December 2017 New drug information Juluca (dolutegravir/rilpivirine): Viiv Healthcare received U.S. Food and Drug Administration
Pulmonary Arterial Hypertension Drug Prior Authorization Protocol
Pulmonary Arterial Hypertension Drug Prior Authorization Protocol Line of Business: Medicaid P&T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has been developed through review
Therapeutic Class Indications Effective
Mortar & Pestle A Publication of Walgreens Health Initiatives July 30, 2009 A publication created especially for our clients and associates, delivering up-to-date information about brand-name and generic,